15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy
Key Takeaways
Clinical classification uses information from diagnosis until the start of treatment or a decision for watchful waiting or supportive care, or four months after diagnosis, whichever is shorter, as long as the cancer has not clearly progressed.
Pathological classification adds surgical findings through completion of definitive surgery or four months after diagnosis, whichever is longer, provided no systemic or radiation therapy was given first and the cancer has not clearly progressed.
After neoadjuvant therapy, the case keeps its clinical classification, gets yc if sampled after treatment and yp from the resection, and the pathological (p) classification does not apply.
Metastasis or progression discovered after the time frame ends is not added to the stage; findings in the time frame, including those from other facilities, are.
Recurrence (r) staging does not replace the original stage, and autopsy (a) staging is used only when cancer is first found at autopsy.
The clinical classification (cTNM)
Sources: physical examination, imaging, endoscopy, laboratory tests, biopsy (including sentinel node biopsy for some sites), and surgical exploration without resection.
Time frame: from diagnosis until the start of treatment (or a decision for watchful waiting or supportive care) or four months after diagnosis, whichever is shorter, as long as the cancer has not clearly progressed.
Key points:
- Every analytic case (Class of Case 10–22) gets a clinical classification, even if surgery comes first.
- A biopsy of the primary in the clinical time frame is still clinical information.
- Microscopically confirmed distant metastasis found during clinical staging is recorded as pM1 within the clinical classification, and it makes the clinical stage group IV.
- Nodes are cN unless microscopically assessed. Some chapters allow cN1(f) after a positive FNA or core biopsy of a node.
The pathological classification (pTNM)
Sources: everything in the clinical classification plus findings from the surgical resection and pathology.
Time frame: through completion of definitive surgery in the first course of treatment, or four months after diagnosis, whichever is longer, as long as:
- no systemic or radiation therapy was given before the surgery, and
- the cancer has not clearly progressed.
Requirements:
- The resection must meet the chapter's criteria for pT. As Section 15.1 explains, microscopic confirmation of the highest T or N category can also be enough.
- If the primary is not resected, pathological T is usually not assigned. The exception is proof of the highest category or pM1.
- Clinical information carries forward. For example, a distant metastasis seen only on imaging (cM1) remains part of the pathological stage.
Post-therapy classifications (yc and yp)
Neoadjuvant therapy means systemic, radiation, or combined therapy given before planned surgery, for a guideline-supported reason.
| Classification | When | Notes |
|---|---|---|
| cTNM | Before neoadjuvant therapy | Still required; it records the pre-treatment extent |
| ycTNM | After neoadjuvant therapy or primary systemic or radiation therapy, from clinical assessment or biopsy, before surgery | STORE items start at 1062 (2021+) |
| ypTNM | Resection after neoadjuvant therapy | Measures response. For example, ypT0 ypN0 is a pathologic complete response |
| pTNM | Not assigned, because the pathological criteria (surgery without prior therapy) are not met | Code 88 is not used for this; STORE reserves 88 for tumors AJCC does not stage |
More post-therapy rules:
- M is carried from the pre-treatment classification. A patient who had M1 before neoadjuvant therapy stays M1, so stage IV for most sites, even if the metastasis disappears.
- ypT is based on the residual invasive tumor. Treatment-related fibrosis is not counted as tumor. Each chapter explains how to measure residual disease.
- If therapy was given for unconventional reasons (for example, the patient's preference not supported by guidelines), the case may not qualify for y classification. Follow the chapter guidance.
Progression and time frame boundaries
- Clearly progressed disease during the time frame ends that classification. Findings after that point are not used.
- A metastasis discovered after the time frame is not added to the original stage. It is follow-up information (recurrence or progression).
- Findings from other facilities within the time frame are used. Stage is based on all available information, not only your facility's records.
Recurrence (r) and autopsy (a)
- rTNM stages a recurrence or retreatment. Registries do not replace the original stage with it.
- aTNM applies when the cancer is first found at autopsy. If cancer was diagnosed during life and the patient died during the pathological time frame, autopsy findings can contribute to that classification. For example, the Grade Manual's autopsy examples follow the same logic.
Worked cases
| Scenario | Classifications to record |
|---|---|
| Breast cancer: imaging and core biopsy, then lumpectomy with sentinel nodes, no neoadjuvant therapy | cTNM from the workup; pTNM from the lumpectomy plus clinical data; yc and yp blank |
| Rectal cancer: MRI cT3 cN1 cM0, then chemoradiation, then low anterior resection showing ypT2 ypN0 | cT3 cN1 cM0 (clinical); ypT2 ypN0 cM0 (post-therapy); pTNM not assigned |
| Prostate cancer: biopsy, then active surveillance | cTNM only; pathological classification not assigned |
| Lung cancer: biopsy-proven adrenal metastasis at diagnosis, palliative chemotherapy | Clinical includes pM1b, stage IV. Pathological stage IV is also allowed because metastasis was microscopically confirmed |
| Colon cancer resected in March, liver metastasis first found in September | The September finding is outside the time frame, so it is not added. Record it as recurrence or progression |
Time frame summary
| Classification | Ends |
|---|---|
| Clinical | Start of treatment, or four months after diagnosis, whichever is shorter |
| Pathological | End of definitive surgery, or four months after diagnosis, whichever is longer (no neoadjuvant therapy) |
| Summary Stage 2018 | Four months after diagnosis, or completion of first-course surgery, whichever is longer (Section 15.6) |
A patient with rectal adenocarcinoma is staged cT3 cN1a cM0 on MRI. After chemoradiation, the low anterior resection shows ypT1 ypN0. Which classifications are recorded?
pT1 pN0 cM0 only, because the resection is the most accurate information
cT3 cN1a cM0 and pT1 pN0 cM0
cT3 cN1a cM0 as the clinical classification and ypT1 ypN0 cM0 as the post-therapy pathological classification; pathological (p) TNM is not assigned
ypT1 ypN0 cM0 only, replacing the clinical stage
A patient's colon cancer is resected on January 10 (pT3 pN0). A CT scan in July, done for new symptoms, shows liver metastases. How is the July finding handled?
The pathological stage is updated to pM1 because it is within six months of diagnosis.
The clinical stage is updated to cM1.
It is not added to the original stage; metastasis found after the staging time frame and after the disease has clearly progressed is recorded as recurrence or progression.
The case is restaged with the r prefix, replacing the original stage.
A lung cancer patient has a biopsy-proven liver metastasis during the initial workup and receives only systemic therapy. Which statement is correct?
The microscopically confirmed metastasis is pM1, and stage IV can be assigned in both the clinical and pathological classifications.
Only a clinical stage can be assigned, so the pathological stage group is always 99.
The M category is cM1 because the primary was not resected.
The case must be staged with the yc prefix because systemic therapy was given.
Sections you finish are checked off in the contents.